Lapsed Jun 16, 2024 on the fee record · Medium confidence
20-year base term ended Apr 25, 2026
Why Medium: A parent in the chain could not be resolved.
First maintenance fee unpaid; grace period ended.
Held by Vivex Biologics Group, Inc.
Filed Sep 26, 2017 as application 15/716,262 · Granted Jun 16, 2020
Base term, 20 years from filing
Today
Lapsed Jun 16, 2024
2006
2026
Clock starts
Apr 25, 2006
Apr 25, 2006
No longer in force
Jun 16, 2024
Jun 16, 2024
Granted
Jun 16, 2020
Jun 16, 2020
Term would have run to
Apr 25, 2026
Apr 25, 2026
base term
after the term ends
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
0 of 1
Maintenance fees paid
One maintenance fee can end this term early, the one due 3.5 years from grant; the next one's grace period runs past the term end. This counts it if the record shows it paid.
6
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
Its term would have run to Apr 25, 2026: its 20-year base term, with no adjustment for prosecution delay. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 25, 2006, when application 11/411,745, the earliest non-provisional in its chain, was filed (this one was filed Sep 26, 2017); a parent in its chain could not be resolved (the next row) | Apr 25, 2026 | High confidence |
| Continuity chain | A parent in the chain could not be resolved | dated from this application's own claim | Medium confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 1 maintenance fees paid | lapsed Jun 16, 2024 | High confidence |
| Computed term end | The steps above, in order | Jun 16, 2024 | Medium confidence |
This family
| US 9,327,010 | Term ended Apr 2026 | Apr 2026 |
| US 9,162,005 | In force Feb 2030 | Feb 2030 |
| US 9,364,513 | Term ended Apr 2026 | Apr 2026 |
| US 9,789,157 | Term ended Apr 2026 | Apr 2026 |
| US 11,839,694 | In force no later than Nov 2026 | no later than Nov 2026 |
| US 10,682,386 | this patent Jun 2024 | Jun 2024 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 26, 2017 Reel 43706, frame 358 | Ellis-behnke, Rutledge; Norchi, Terrence W.; Kelly, Stephen | Clear Nano Solutions, Inc. | Assignment of Assignor's Interest |
| Sep 26, 2017 Reel 43706, frame 415 | Arch Therapeutics, Inc.; Arch Acquisition Corporation; Arch Biosurgery, Inc. | Arch Biosurgery, Inc. | Merger and Change of Name |
| Sep 26, 2017 Reel 44017, frame 485 | Clear Nano Solutions, Inc. | Arch Therapeutics, Inc. | Change of Name |
| Jul 23, 2025 Reel 71810, frame 537 | Arch Therapeutics, Inc.; Arch Biosurgery, Inc. | Arch Acquisition LLC | Assignment of Assignor's Interest |
| Jul 23, 2025 Reel 71810, frame 682 | Arch Acquisition LLC | Vivex Biologics Group, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Citations
21
later US patents cite this one
That is top 10% of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.